Pleural effusion - Pipeline Insight, 2024

Pleural effusion - Pipeline Insight, 2024

DelveInsight’s, “Pleural effusion - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pleural effusion pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pleural effusion Understanding

Pleural effusion: Overview

Pleural effusion is the accumulation of fluid in between the parietal and visceral pleura, called the pleural cavity. It can occur by itself or can be the result of surrounding parenchymal disease like infection, malignancy, or inflammatory conditions. Pleural effusion is one of the major causes of pulmonary mortality and morbidity. All healthy humans have a small amount of pleural fluid that lubricates the space and facilitates normal lung movements during respiration. This delicate balance of fluid is maintained by the oncotic and hydrostatic pressure and lymphatic drainage; disturbances in any one of these systems can lead to a build-up of pleural fluid. As pleural effusion is the result of varied diseases, history and physical examination should also be focused on the underlying pulmonary or systemic cause of the effusion. For example, in congestive heart failure (CHF), examine for jugular venous distension, S3, and pedal edema; in cirrhosis leading to hepatic hydrothorax, look for ascites and other stigmata of liver disease.

""Pleural effusion - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pleural effusion pipeline landscape is provided which includes the disease overview and Pleural effusion treatment guidelines. The assessment part of the report embraces, in depth Pleural effusion commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pleural effusion collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Pleural effusion.
• In the coming years, the Pleural effusion market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Pleural effusion R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Pleural effusion treatment market. Several potential therapies for Pleural effusion are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Pleural effusion market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Pleural effusion) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Pleural effusion Emerging Drugs Chapters

This segment of the Pleural effusion report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pleural effusion Emerging Drugs

• LTI-01: Lung Therapeutics

LTI-01 is the first pharmaceutical agent specifically developed for treating non-draining Loculated Pleural Effusion (LPE). LTI-01 has completed a Phase 1b clinical trial demonstrating preliminary signs of efficacy with no safety concerns. LTI-01 is a proenzyme, or zymogen, that breaks down the fibrinous adhesions that cause LPE. LTI-01 has demonstrated a longer, more sustained activity than fibrinolytics used off label. The mechanism and preclinical and clinical data of LTI-01 suggest that it will have a better safety and efficacy profile compared to off label fibrinolytic drugs.

• M701: Wuhan YZY Biopharma

M701 is a recombinant anti-EpCAM and CD3 human-mouse chimeric bispecific antibody product for injection. Using the independently innovative YBODY ® platform technology, one end targets the EpCAM antigen highly expressed by tumor cells, and the other end targets the CD3 antigen on the surface of immune T cells. By targeting EpCAM antigen and CD3 antigen, T cells are recruited to tumor cells, and T cells are activated for immune killing of tumor cells, thereby inhibiting the growth of tumor cells, relieving or eliminating the obstruction of lymphatic vessels and peritoneal damage by tumor cells, and then The symptoms of malignant ascites in patients can be controlled, relieved and eliminated.

Further product details are provided in the report……..

Pleural effusion: Therapeutic Assessment

This segment of the report provides insights about the different Pleural effusion drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Pleural effusion

There are approx. 5+ key companies which are developing the therapies for Pleural effusion. The companies which have their Pleural effusion drug candidates in the most advanced stage, i.e. phase II include, Lung Therapeutics.

• Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Pleural effusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pleural effusion: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pleural effusion therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pleural effusion drugs.

Pleural effusion Report Insights

• Pleural effusion Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pleural effusion Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pleural effusion drugs?
• How many Pleural effusion drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pleural effusion?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pleural effusion therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pleural effusion and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Lung Therapeutics
• Wuhan YZY Biopharma Co., Ltd.
• RS Oncology
• Wuhan Binhui Biotechnology Co., Ltd
• Sichuan Clover Biopharmaceuticals, Inc.
• LIPAC Oncology

Key Products

• LTI-01
• M701
• RSO-021
• Virus Activated Killer immune Cells
• SCB-313
• LEITP-1009